Flares Occur Frequently in Generalized Pustular Psoriasis
By Elana Gotkine HealthDay Reporter
WEDNESDAY, April 16, 2025 -- Patients with generalized pustular psoriasis (GPP) experience frequent flares, and treatment alterations of off-label agents are frequently observed, according to a study recently published online in the Journal of the American Academy of Dermatology.
Jamie L.W. Rhoads, M.D., from the University of Utah School of Medicine in Salt Lake City, and colleagues characterized patients by GPP flare status, quantified flare timing/frequency, and examined periflare treatment patterns in a cohort study using electronic health records from 2017 to 2023 from outpatient dermatology clinics. Patients were indexed at first GPP diagnosis code.
The researchers found that 404 of the 638 patients (63 percent) experienced one or more flare episodes. The likelihood of experiencing a flare was higher for patients who were female, younger, non-White, and Hispanic/Latino; those who had infectious/parasitic disease history; and those with more active GPP. The mean annualized flare rate was 0.91 flares per patient per year; between flares, there was a mean of 5.9 months. There was an increase seen in prescriptions from the preflare period to flare episode, followed by a decrease during the postflare period. There were frequent treatment alterations of off-label biologics and nonsteroidal systemic agents.
"Treatment strategy for GPP flares is not standardized, and the course of medication in periflare time periods was often altered," the authors write. "High discontinuation and switching rates among biologic users suggest the need for more effective long-term GPP treatments."
Several authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted April 2025
Read this next
Central Adiposity Measures Associated With Psoriasis Risk
TUESDAY, June 3, 2025 -- Central adiposity measures are strongly associated with psoriasis risk, with a stronger association in women, according to a research letter published...
Psoriasis Tied to Increased Risk for Sleep Disorders
MONDAY, June 2, 2025 -- Both mild and moderate-to-severe psoriasis are significantly associated with an increased risk for sleep disorders, according to a study published online...
Residual Inflammation Seen in One-Third of Patients With Psoriasis on Biologics
WEDNESDAY, May 21, 2025 -- For patients with psoriasis receiving biologic therapy, residual inflammation (RI), defined as increased inflammatory markers in blood, characterized by...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.